Increased gene expression of TIMP1 and CHI3L1 in fine-needle aspiration biopsy samples from papillary thyroid cancer as compared to benign nodules.
chitinase-3-like protein 1
papillary thyroid cancer
qPCR
thyroid fine-needle aspiration biopsy
tissue inhibitor of metalloproteinase-1
Journal
Diagnostic cytopathology
ISSN: 1097-0339
Titre abrégé: Diagn Cytopathol
Pays: United States
ID NLM: 8506895
Informations de publication
Date de publication:
Sep 2021
Sep 2021
Historique:
revised:
02
06
2021
received:
04
04
2021
accepted:
08
06
2021
pubmed:
26
6
2021
medline:
4
1
2022
entrez:
25
6
2021
Statut:
ppublish
Résumé
Thyroid nodules are common ultrasound findings with malignancy rate 7%-15%. Our objective was to assess the relative expression of the tissue inhibitor of metalloproteinase-1 gene (TIMP1) and chitinase-3-like protein 1 gene (CHI3L1) in fine-needle aspiration biopsy (FNAB) washouts and the serum levels of their protein products (TIMP-1 and chitinase-3-like protein 1 known as YKL-40) in patients with papillary thyroid cancer (PTC) and patients with benign nodules. Furthermore, the correlation between gene expression and circulating protein product was evaluated. Eighty patients who underwent FNAB in one tertiary center were recruited in the study. Forty with Bethesda V and VI nodules were operated and PTC was confirmed. The other 40 patients were with Bethesda II nodules. TIMP-1 and YKL-40 serum levels were measured in all subjects. The TIMP1 and CHI3L1 expression was assessed in FNAB washouts from 20 PTC patients and 20 benign cases using quantitative PCR. The relative expression of TIMP1 and CHI3L1 was significantly higher in the PTC group than in the benign group (p < .001 for TIMP1; p = .018 for CHI3L1). The PTC patients had higher serum TIMP-1 than the patients with benign nodules (p = .036). We did not find significant difference in the YKL-40 level between the two groups. TIMP1 and CHI3L1 expression did not correlate with the serum levels of their protein products. FNAB washouts could be used for identification of diagnostic markers. The increased TIMP1 and CHI3L1 expression implies a role of these genes in the PTC carcinogenesis.
Sections du résumé
BACKGROUND
BACKGROUND
Thyroid nodules are common ultrasound findings with malignancy rate 7%-15%. Our objective was to assess the relative expression of the tissue inhibitor of metalloproteinase-1 gene (TIMP1) and chitinase-3-like protein 1 gene (CHI3L1) in fine-needle aspiration biopsy (FNAB) washouts and the serum levels of their protein products (TIMP-1 and chitinase-3-like protein 1 known as YKL-40) in patients with papillary thyroid cancer (PTC) and patients with benign nodules. Furthermore, the correlation between gene expression and circulating protein product was evaluated.
METHODS
METHODS
Eighty patients who underwent FNAB in one tertiary center were recruited in the study. Forty with Bethesda V and VI nodules were operated and PTC was confirmed. The other 40 patients were with Bethesda II nodules. TIMP-1 and YKL-40 serum levels were measured in all subjects. The TIMP1 and CHI3L1 expression was assessed in FNAB washouts from 20 PTC patients and 20 benign cases using quantitative PCR.
RESULTS
RESULTS
The relative expression of TIMP1 and CHI3L1 was significantly higher in the PTC group than in the benign group (p < .001 for TIMP1; p = .018 for CHI3L1). The PTC patients had higher serum TIMP-1 than the patients with benign nodules (p = .036). We did not find significant difference in the YKL-40 level between the two groups. TIMP1 and CHI3L1 expression did not correlate with the serum levels of their protein products.
CONCLUSION
CONCLUSIONS
FNAB washouts could be used for identification of diagnostic markers. The increased TIMP1 and CHI3L1 expression implies a role of these genes in the PTC carcinogenesis.
Substances chimiques
Biomarkers, Tumor
0
CHI3L1 protein, human
0
Chitinase-3-Like Protein 1
0
TIMP1 protein, human
0
Tissue Inhibitor of Metalloproteinase-1
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1045-1051Subventions
Organisme : Medical University of Sofia
ID : D-123
Informations de copyright
© 2021 Wiley Periodicals LLC.
Références
Guth S, Theune U, Aberle J, Galach A, Bamberger CM. Very high prevalence of thyroid nodules detected by high frequency (13 MHz) ultrasound examination. Eur J Clin Invest. 2009;39(8):699-706.
Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26(1):1-133.
Noone AM, Howlader N, Krapcho M, Miller D, Brest A, Yu M, et al. SEER Cancer Statistics Review, 1975-2015. Based on November 2017 SEER data submission, posted to the SEER web site, April 2018. https://seer.cancer.gov/csr/1975_2015/.
Cabanillas ME, McFadden DG, Durante C. Thyroid cancer. Lancet. 2016;388(10061):2783-2795.
Castro MR, Gharib H. Thyroid fine-needle aspiration biopsy: progress, practice, and pitfalls. Endocr Pract. 2003;9(2):128-136.
Cibas ES, Ali SZ. The 2017 Bethesda system for reporting thyroid cytopathology. J Am Soc Cytopathol. 2017;6(6):217-222.
Labourier E, Shifrin A, Busseniers AE, et al. Molecular testing for miRNA, mRNA, and DNA on fine-needle aspiration improves the preoperative diagnosis of thyroid nodules with indeterminate cytology. J Clin Endocrinol Metab. 2015;100(7):2743-2750.
Patel KN, Angell TE, Babiarz J, et al. Performance of a genomic sequencing classifier for the preoperative diagnosis of cytologically indeterminate thyroid nodules. JAMA Surg. 2018;153(9):817-824.
Nikiforova MN, Mercurio S, Wald AI, et al. Analytical performance of ThyroSeq v3 genomic classifier for cancer diagnosis in thyroid nodules. Cancer. 2019;124(8):1682-1690.
Steward DL, Carty SE, Sippel RS, et al. Performance of a multigene genomic classifier in thyroid nodules with indeterminate cytology: a prospective blinded multicenter study. JAMA Oncol. 2019;5(2):204-212.
Angell TE, Wirth LJ, Cabanillas ME, et al. Analytical and clinical validation of expressed variants and fusions from the whole transcriptome of thyroid FNA samples. Front Endocrinol. 2019;10:612.
Huang Y, Prasad M, Lemon WJ, et al. Gene expression in papillary thyroid carcinoma reveals highly consistent profiles. Proc Natl Acad Sci USA. 2001;98(26):15044-15049.
Barros-Filho MC, Marchi FA, Pinto CA, Rogatto SR, Kowalski LP. High diagnostic accuracy based on CLDN10, HMGA2, and LAMB3 transcripts in papillary thyroid carcinoma. J Clin Endocrinol Metab. 2015;100(6):E890-E899.
Ferris RL, Baloch Z, Bernet V, et al. American Thyroid Association statement on surgical application of molecular profiling for thyroid nodules : current impact on perioperative decision making. Thyroid. 2015;25(7):760-768.
Nikiforova MN, Biddinger PW, Caudill CM, Kroll TG, Nikiforov YE. PAX8-PPARgamma rearrangement in thyroid tumors: RT-PCR and immunohistochemical analyses. Am J Surg Pathol. 2002;26(8):1016-1023.
Prasad NB, Kowalski J, Tsai HL, et al. Three-gene molecular diagnostic model for thyroid cancer. Thyroid. 2012;22(3):275-284.
Gonzalez HE, Martinez JR, Vargas-Salas S, et al. A 10-gene classifier for indeterminate thyroid nodules: development and multicenter accuracy study. Thyroid. 2017;27(8):1058-1067.
Nikolova DN, Zembutsu H, Sechanov T, et al. Genome-wide gene expression profiles of thyroid carcinoma: identification of molecular targets for treatment of thyroid carcinoma. Oncol Rep. 2008;20(1):105-121.
Komorowski J, Pasieka Z, Jankiewicz-Wika J, Stepien H. Matrix metalloproteinases, tissue inhibitors of matrix metalloproteinases and angiogenic cytokines in peripheral blood of patients with thyroid cancer. Thyroid. 2002;12(8):655-662.
Makki FM, Taylor SM, Shahnavaz A, et al. Serum biomarkers of papillary thyroid cancer. J Otolaryngol Head Neck Surg. 2013;42(1):16.
Omran MM, Darwish H, Fawzy Y, Hegazy MAF, Malak CAA. A novel score based on galectin-3 and tissue inhibitor of metalloproteinase-1 improves the diagnostic accuracy of thyroid cancer. Int J Sci Eng Res. 2017;8(12):673-678.
Kebebew E, Peng M, Reiff E, McMillan A. Diagnostic and extent of disease multigene assay for malignant thyroid neoplasms. Cancer. 2006;106(12):2592-2597.
Kebebew E, Peng M, Reiff E, et al. Diagnostic and prognostic value of angiogenesis-modulating genes in malignant thyroid neoplasms. Surgery. 2005;138(6):1102-1109.
Mathur A, Weng J, Moses W, et al. A prospective study evaluating the accuracy of using combined clinical factors and candidate diagnostic markers to refine the accuracy of thyroid fine needle aspiration biopsy. Surgery. 2010;148(6):1170-1177.
Sadowski SM, Petrenko V, Meyer P, et al. Validation of molecular biomarkers for preoperative diagnostics of human papillary thyroid carcinoma in fine needle aspirates. Gland Surg. 2019;8(2):62-76.
Maeta H, Ohgi S, Terada T. Protein expression of matrix metalloproteinases 2 and 9 and tissue inhibitors of metalloproteinase 1 and 2 in papillary thyroid carcinomas. Virchows Arch. 2001;438(2):121-128.
Zhang WJ, Song B, Yang T. MMP-2, MMP-9, TIMP-1, and TIMP-2 in the peripheral blood of patients with differentiated thyroid carcinoma. Cancer Manag Res. 2019;11:10675-10681.
Lipton A, Leitzel K, Chaudri-Ross HA, et al. Serum TIMP-1 and response to the aromatase inhibitor letrozole versus tamoxifen in metastatic breast cancer. J Clin Oncol. 2008;26(16):2653-2658.
Ilie MI, Lassalle S, Long-Mira E, et al. In papillary thyroid carcinoma, TIMP-1 expression correlates with BRAF (V600E) mutation status and together with hypoxia-related proteins predicts aggressive behavior. Virchows Arch. 2013;463(3):437-444.
Bommarito A, Richiusa P, Carissimi E, et al. BRAF V600E mutation, TIMP-1 upregulation and NF-kB activation: closing the loop on the papillary thyroid cancer trilogy. Endocr Relat Cancer. 2011;18(6):669-685.
Hamada A, Mankovskaya S, Saenko V, et al. Diagnostic usefulness of PCR profiling of the differentially expressed marker genes in thyroid papillary carcinomas. Cancer Lett. 2005;224(2):289-301.
Luo D, Chen H, Lu P, et al. CHI3L1 overexpression is associated with metastasis and is an indicator of poor prognosis in papillary thyroid carcinoma. Cancer Biomark. 2017;18(3):273-284.
Cheng SP, Lee JJ, Chang YC, Lin CH, Li YS, Liu CL. Overexpression of chitinase-3-like protein 1 is associated with structural recurrence in patients with differentiated thyroid cancer. J Pathol. 2020;252(2):114-124.
Lian M, Cao H, Baranova A, et al. Aging-associated genes TNFRSF12A and CHI3L1 contribute to thyroid cancer: an evidence for the involvement of hypoxia as a driver. Oncol Lett. 2020;19(6):3634-3642.
Zhou SF, Hu SY, Ma L, Miao L, Mao WZ. Correlations between papillary thyroid cancer and peripheral blood levels of matrix metalloproteinase-2, matrix metalloproteinase-9, tissue inhibitor of metalloproteinase-1, and tissue inhibitor of metalloproteinase-2. Chin Med J (Engl). 2013;126(10):1925-1929.
Lin SY, Wang YY, Sheu WH. Preoperative plasma concentrations of vascular endothelial growth factor and matrix metalloproteinase 9 are associated with stage progression in papillary thyroid cancer. Clin Endocrinol (Oxf). 2003;58(4):513-518.
Kobawala TP, Trivedi TI, Gajjar KK, Patel DH, Patel GH, Ghosh NR. Significance of Interleukin-6 in papillary thyroid carcinoma. J Thyroid Res. 2016;2016:6178921.
Lichtinghagen R, Musholt PB, Lein M, et al. Different mRNA and protein expression of matrix metalloproteinases 2 and 9 and tissue inhibitor of metalloproteinases 1 in benign and malignant prostate tissue. Eur Urol. 2002;42(4):398-406.
Sarro SM, Unruh TL, Zuccolo J, et al. Quantification of CD20 mRNA and protein levels in chronic lymphocytic leukemia suggests a post-transcriptional defect. Leuk Res. 2010;34(12):1670-1673.
Moretz WH 3rd, Gourin CG, Terris DJ, et al. Detection of papillary thyroid carcinoma with serum protein profile analysis. Arch Otolaryngol Head Neck Surg. 2008;134(2):198-202.
Vogel C, Marcotte EM. Insights into the regulation of protein abundance from proteomic and transcriptomic analyses. Nat Rev Genet. 2012;13(4):227-232.
Lee L, How J, Tabah RJ, Mitmaker EJ. Cost-effectiveness of molecular testing for thyroid nodules with atypia of undetermined significance cytology. J Clin Endocrinol Metab. 2014;99(8):2674-2682.